Cowen analyst Tyler Van Buren reiterated an Outperform rating on Iovanace Biotherapeutics (NASDAQ: IOVA), following announcement of a 2-month delay ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE